Liberty One Investment Management LLC Purchases 563 Shares of Amgen Inc. $AMGN

Liberty One Investment Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 16,724 shares of the medical research company’s stock after acquiring an additional 563 shares during the quarter. Liberty One Investment Management LLC’s holdings in Amgen were worth $4,669,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Amgen by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock worth $3,662,000 after purchasing an additional 3,369 shares in the last quarter. First Bancorp Inc ME purchased a new stake in Amgen during the 1st quarter worth about $234,000. Ridgecrest Wealth Partners LLC lifted its holdings in Amgen by 10.2% during the 1st quarter. Ridgecrest Wealth Partners LLC now owns 4,877 shares of the medical research company’s stock worth $1,519,000 after purchasing an additional 450 shares in the last quarter. Finally, Flagship Harbor Advisors LLC lifted its holdings in Amgen by 4.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 3,078 shares of the medical research company’s stock worth $959,000 after purchasing an additional 124 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $303.33 on Tuesday. The firm has a market cap of $163.30 billion, a P/E ratio of 24.80, a P/E/G ratio of 2.64 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88. The business’s 50 day moving average price is $287.51 and its 200-day moving average price is $287.05. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.1%. Amgen’s payout ratio is currently 77.84%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.69% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Piper Sandler increased their price objective on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Sunday. Citigroup raised their price target on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Finally, Weiss Ratings raised Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $300.94.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.